Beta

Spending
Congress
Stocks
Lobbying

Spending
Congress
Stocks
Lobbying

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Congress
Stocks
Lobbying

LD-2 disclosure · 2nd Quarter - Report

PSYCHEDELIC MEDICINE COALITION

via THE CONAFAY GROUP, LLC

2nd Quarter (Apr 1 - June 30) · 2023Posted Jul 20, 2023Filing document ↗LDA record ↗

Coverage · No income or expenses were reported on this filing.

Client

Name: PSYCHEDELIC MEDICINE COALITION
Description: A coaltion that advocates on behalf of safe access to psychadelic medicines.
Location: District of Columbia · United States of America

Registrant

Firm: THE CONAFAY GROUP, LLC
Description: Life Sciences Consulting Firm
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Health Issues
Education & Advocacy for issues related to alternative treatments for mental health issues and research in treating behavioral health challenges.
LobbyistsJOSH NARROW · mr DARIN L GARDNER
Covered position (JOSH NARROW): Intern for Senator Casey
Covered position (mr DARIN L GARDNER): Legislative Correspondent to Senator Tim Hutchinson; Research Assistant forSenateHELP Committee; Chief of Staff for Congresswoman Kay Granger
TargetedSENATE · HOUSE OF REPRESENTATIVES · Health & Human Services, Dept of (HHS) · Veterans Affairs, Dept of (VA)

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.

PSYCHEDELIC MEDICINE COALITION — Lobbying — Receipts Report